Cadrenal Therapeutics, Inc. Accounts Payable
Cadrenal Therapeutics, Inc. (CVKD) had Accounts Payable of $871.91 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-13
- 2026-06-30: Accounts Payable, Current $871.91K.
- 2026-03-31: Accounts Payable, Current $824.81K.
- 2025-12-31: Accounts Payable, Current $650.66K.
- 2025-09-30: Accounts Payable, Current $614.13K.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $871.91K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $824.81K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $650.66K 10-Q · filed 2026-08-13 |
| 2025-09-30 | $614.13K 10-Q · filed 2025-11-10 |
| 2025-06-30 | $895.61K 10-Q · filed 2025-08-11 |
| 2025-03-31 | $1.28M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.50M 10-K · filed 2026-03-31 |
| 2024-09-30 | $496.82K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $759.52K 10-Q · filed 2024-08-07 |
| 2024-03-31 | $400.37K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $167.32K 10-K · filed 2025-03-13 |
| 2023-09-30 | $141.66K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $78.14K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $119.57K 10-Q · filed 2023-05-10 |
| 2022-12-31 | $404.90K 10-K · filed 2024-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |